An interventional study of Ecological Momentary Assessment (EMA) and Biological assessment in Stroke, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-21.
Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Stroke by University Hospital, Bordeaux — 9 open to participants now, 10 under way, 2 of them phase 3. Stroke · University Hospital, Bordeaux.
Among the 27 studies in Stroke by University Hospital, Bordeaux, this one is the 3rd largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2025, is one of 17 with no phase, and was the 24th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →9 of the 27 studies in Stroke by University Hospital, Bordeaux are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Bordeaux · Sites in France
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages 18–75
University Hospital, Bordeaux · Sites in France
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages 18–80
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 388 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 166 across the 22 interventional studies, 1,138 across the 5 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
5 of the studies in Stroke by University Hospital, Bordeaux that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03998852Phase 3University Hospital, BordeauxIn Vivo Involvement of the Cholinergic and Dopaminergic Systems in the Pathophysiology of Apathy. | 2027-04-13 |
| NCT06059144Phase 3University Hospital, BordeauxInduced Hypertension in Acute PRogrESsive Perforating Artery Stroke Using Peripheral Dilute noREpinephrine | 2027-08-28 |
| NCT06837311University Hospital, BordeauxPost-Stroke Secondary Prevention With Digital Monitoring | 2027-03-25 |
| NCT04796714University Hospital, BordeauxAntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE | 2027-05-03 |
| NCT05306834University Hospital, BordeauxStopping Cognitive Decline and Dementia by Fighting Covert Cerebral Small Vessel Disease | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 27 studies in Stroke by University Hospital, Bordeaux, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Stroke is the second leading cause of death and a major cause of disability worldwide. In 2019, Disability-Adjusted Life-Years (DALYs) related to stroke was estimated to have reached 143 million. Modifiable stroke risk-factors, which include poor lifestyle habits (tobacco, alcohol and illicit drug abuse, dietary patterns at risk, low physical activity), account for 90 % of the risk of stroke. Stroke complications and the risk of stroke recurrence is highly dependent on the control of these risk factors. Thus, the secondary prevention of stroke requires profound lifestyle modifications including substance use cessation and diet changes. National guidelines for stroke clinical practice advocate an immediate cessation of consumption of all substances but without recommendations on specific therapeutic regimens. Moreover, none address the management of poor coping with stress or mood problems though they are major population attributable risk factors of stroke and constitute major barriers of behavior changes achievement. Yet, post-stroke emotional impairments are frequent, post-stroke depression and anxiety being the most frequent (prevalence is 30% and 25%, respectively). Importantly, independently from stroke, emotional impairments or disorders and Substance Related and Addiction Disorders (SRADs) are frequent comorbid conditions (dual disorders) with debilitating consequences and the interplay between the two conditions makes rehabilitation more complex. This suggests that taking into account stroke patients' mental health status might improve not only the management of post-stroke emotional impairments but also the control of stroke vascular risk factors.
Regarding secondary prevention programs focusing on behavioral changes among Cardiovascular and Cerebrovascular Disease (CVD) patients, the literature is sparse and studies on smoking cessation are the most widely documented. Despite the risk of smoking after a myocardial infarct or a stroke/Transient Ischemic Attack (TIA), less than half of patients quit smoking after the event or achieve long-term abstinence.
To increase treatment adherence and efficacy, besides systematically screening lifestyle habits and evaluating the patients' mental health and motivation to change in clinical routine, experts in the domain emphasize the need to:
After hospital discharge, in standard care, the follow-up visit is scheduled 4 to 6 months post-stroke. Knowing that the vast majority of smoking relapses occur in the weeks following stroke, it appears that this period is of high risk for missing the goal of stroke secondary prevention. Therefore, new approaches are urgently needed that would allow for the day-to-day examination of clinical change in the immediate days and weeks following discharge from the stroke acute-care unit to optimize the patient's recovery and quality of life.
The potential pivotal role of eHealth development has been advocated by the World Health Organization, which considers e-Health as a cost-effective and secure use of information and communication technologies (ICT). Used in the context of stroke secondary prevention, eHealth technologies should give each patient the opportunity to describe his/her own experiences and symptoms and the contexts of daily life in which they occur that may constitute negative factors for post-stroke recovery. Post-stroke management would thus be optimized through a person-centered, intense and multidisciplinary care program.
Investigators believe apTeleCare would allow for such a day-to-day examination of clinical change in the immediate days and weeks following discharge from the stroke acute-care unit. It offers the possibility not only to closely monitor patients' experiences and symptoms and the contexts of daily life in which they occur, but also to inform the clinical team in real-time via specific alerts that depend on the type and level of difficulties the patients encounter for adopting the expected changes in their lifestyle
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Ecological Momentary Assessment (EMA) · Biological: Biological assessment · Behavioral: Psychological examination and Substance Use symptomatology · Other: Treatment as usual (TAU) · Diagnostic Test: Expired carbon monoxide (CO)
Biological: Biological assessment · Behavioral: Psychological examination and Substance Use symptomatology · Other: Treatment as usual (TAU) · Diagnostic Test: Expired carbon monoxide (CO)
Daily ecological momentary assessment (EMA), in addition to treatment as usual (TAU) using apTeleCare eHealth device. Daily surveys includes questions reflecting all Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 symptom criteria for Depression, Generalized Anxiety Disorder, Post-Traumatic Symptom Disorder, evaluations of substance use (including dietary items at risk) as well as of two symptoms predictive of relapse (craving and loss of control), medication compliance and physical activity
Routine Biological assessment and of substance use
Substance use symptomatology ; Neuropsychiatric symptomatology ; Functional outcomes ; Neurologic and Cardiovascular outcomes
Treatment as usual (TAU)
Expired carbon monoxide (CO) measurement
Expired carbon monoxide (CO) rate
Prevalence tobacco abstinence (Expired CO ≤ 8 ppm) 6 months after acute ward discharge.
Time frame: 6 months
Level of risk and prevalence of Substance-related and addictive disorders (SRADs)
Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). It consists of 8 questions covering tobacco, alcohol, cannabis, amphetamine-type stimulants, inhalants, sedatives, hallucinogens, opiates, and 'other drugs. Twenty-eight domains/scores are derived from these questions
Time frame: Day 0
Level of risk and prevalence of Substance-related and addictive disorders (SRADs)
Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). It consists of 8 questions covering tobacco, alcohol, cannabis, amphetamine-type stimulants, inhalants, sedatives, hallucinogens, opiates, and 'other drugs. Twenty-eight domains/scores are derived from these questions
Time frame: 3 Months
Level of risk and prevalence of Substance-related and addictive disorders (SRADs)
Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). It consists of 8 questions covering tobacco, alcohol, cannabis, amphetamine-type stimulants, inhalants, sedatives, hallucinogens, opiates, and 'other drugs. Twenty-eight domains/scores are derived from these questions
Time frame: 6 Months
Level of risk and prevalence of Substance-related and addictive disorders (SRADs)
Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). It consists of 8 questions covering tobacco, alcohol, cannabis, amphetamine-type stimulants, inhalants, sedatives, hallucinogens, opiates, and 'other drugs. Twenty-eight domains/scores are derived from these questions
Time frame: 12 Months
Fagerström Test for Nicotine Dependence (FTND) score
Nicotine dependence using the Fagerström Test for Nicotine Dependence (FTND) which includes 10 items. Scores can range from 0 to 10. The recommended cut-off scores to index the categories of nicotine dependence severity are as follows: below 2 = no dependence, 3 to 4 = mild severity, 5 to 6 = moderate severity, 7 to 10 = extreme severity.
Time frame: Day 0
Fagerström Test for Nicotine Dependence (FTND) score
Nicotine dependence using the Fagerström Test for Nicotine Dependence (FTND) which includes 10 items. Scores can range from 0 to 10. The recommended cut-off scores to index the categories of nicotine dependence severity are as follows: below 2 = no dependence, 3 to 4 = mild severity, 5 to 6 = moderate severity, 7 to 10 = extreme severity.
Time frame: 3 months
Fagerström Test for Nicotine Dependence (FTND) score
Nicotine dependence using the Fagerström Test for Nicotine Dependence (FTND) which includes 10 items. Scores can range from 0 to 10. The recommended cut-off scores to index the categories of nicotine dependence severity are as follows: below 2 = no dependence, 3 to 4 = mild severity, 5 to 6 = moderate severity, 7 to 10 = extreme severity.
Time frame: 6 months
Fagerström Test for Nicotine Dependence (FTND) score
Nicotine dependence using the Fagerström Test for Nicotine Dependence (FTND) which includes 10 items. Scores can range from 0 to 10. The recommended cut-off scores to index the categories of nicotine dependence severity are as follows: below 2 = no dependence, 3 to 4 = mild severity, 5 to 6 = moderate severity, 7 to 10 = extreme severity.
Time frame: 12 months
modified Yale Food Addiction Scale 2.0 (mYFAS 2.0) score
Includes one question to assess each of the 11 DSM 5 diagnostic criteria for SRADs transposed to food items as well as two questions to assess clinically significant distress and impairment. Food Addiction is mild if there are 2 or 3 symptoms and clinically significant impairment/distress, moderate if there are 4 or 5 symptoms and significant impairment/distress, and severe if there are 6 or more symptoms and significant impairment/distress.
Time frame: Day 0
modified Yale Food Addiction Scale 2.0 (mYFAS 2.0) score
Includes one question to assess each of the 11 DSM 5 diagnostic criteria for SRADs transposed to food items as well as two questions to assess clinically significant distress and impairment. Food Addiction is mild if there are 2 or 3 symptoms and clinically significant impairment/distress, moderate if there are 4 or 5 symptoms and significant impairment/distress, and severe if there are 6 or more symptoms and significant impairment/distress.
Time frame: 3 Months
modified Yale Food Addiction Scale 2.0 (mYFAS 2.0) score
Includes one question to assess each of the 11 DSM 5 diagnostic criteria for SRADs transposed to food items as well as two questions to assess clinically significant distress and impairment. Food Addiction is mild if there are 2 or 3 symptoms and clinically significant impairment/distress, moderate if there are 4 or 5 symptoms and significant impairment/distress, and severe if there are 6 or more symptoms and significant impairment/distress.
Time frame: 6 Months
modified Yale Food Addiction Scale 2.0 (mYFAS 2.0) score
Includes one question to assess each of the 11 DSM 5 diagnostic criteria for SRADs transposed to food items as well as two questions to assess clinically significant distress and impairment. Food Addiction is mild if there are 2 or 3 symptoms and clinically significant impairment/distress, moderate if there are 4 or 5 symptoms and significant impairment/distress, and severe if there are 6 or more symptoms and significant impairment/distress.
Time frame: 12 Months
Alcohol Use Disorder Identification Test (AUDIT) Score
Alcohol dependence test. 10 items. Scores can range from 0 to 40. The recommended cut-off scores to index the categories of alcohol dependence severity are as follows: from 6 to 12 for women and 7 to 12 for men = moderate severity, and above 12 = extreme severity for both sexes.
Time frame: Day 0
Alcohol Use Disorder Identification Test (AUDIT) Score
Alcohol dependence test. 10 items. Scores can range from 0 to 40. The recommended cut-off scores to index the categories of alcohol dependence severity are as follows: from 6 to 12 for women and 7 to 12 for men = moderate severity, and above 12 = extreme severity for both sexes.
Time frame: 3 months
Alcohol Use Disorder Identification Test (AUDIT) Score
Alcohol dependence test. 10 items. Scores can range from 0 to 40. The recommended cut-off scores to index the categories of alcohol dependence severity are as follows: from 6 to 12 for women and 7 to 12 for men = moderate severity, and above 12 = extreme severity for both sexes.
Time frame: 6 months
Alcohol Use Disorder Identification Test (AUDIT) Score
Alcohol dependence test. 10 items. Scores can range from 0 to 40. The recommended cut-off scores to index the categories of alcohol dependence severity are as follows: from 6 to 12 for women and 7 to 12 for men = moderate severity, and above 12 = extreme severity for both sexes.
Time frame: 12 months
Cannabis Abuse Screening Test (CAST) score
6 items. Scores can range from 0 to 6. The recommended cut-off scores to index the categories of cannabis dependence severity are as follows: below 2 = low risk of dependence, a score of 2 = moderate risk of dependence, and 3 or more = high risk of dependence.
Time frame: Day 0
Cannabis Abuse Screening Test (CAST) score
6 items. Scores can range from 0 to 6. The recommended cut-off scores to index the categories of cannabis dependence severity are as follows: below 2 = low risk of dependence, a score of 2 = moderate risk of dependence, and 3 or more = high risk of dependence.
Time frame: 3 Months
Cannabis Abuse Screening Test (CAST) score
6 items. Scores can range from 0 to 6. The recommended cut-off scores to index the categories of cannabis dependence severity are as follows: below 2 = low risk of dependence, a score of 2 = moderate risk of dependence, and 3 or more = high risk of dependence.
Time frame: 6 Months
Cannabis Abuse Screening Test (CAST) score
6 items. Scores can range from 0 to 6. The recommended cut-off scores to index the categories of cannabis dependence severity are as follows: below 2 = low risk of dependence, a score of 2 = moderate risk of dependence, and 3 or more = high risk of dependence.
Time frame: 12 Months
Readiness Ruler or Substance Use Motivation Ruler score
Asks the respondent to rank his/her motivation to end his/her substance use on a Visual Analog Scale from 1 (Absolutely no motivation to quit) to 10 (No doubt about the decision to be sober) and to list some motivations. The participant will be instructed to provide at least one motivation or more if relevant.
Time frame: Day 0
Readiness Ruler or Substance Use Motivation Ruler score
Asks the respondent to rank his/her motivation to end his/her substance use on a Visual Analog Scale from 1 (Absolutely no motivation to quit) to 10 (No doubt about the decision to be sober) and to list some motivations. The participant will be instructed to provide at least one motivation or more if relevant.
Time frame: 3 months
Readiness Ruler or Substance Use Motivation Ruler score
Asks the respondent to rank his/her motivation to end his/her substance use on a Visual Analog Scale from 1 (Absolutely no motivation to quit) to 10 (No doubt about the decision to be sober) and to list some motivations. The participant will be instructed to provide at least one motivation or more if relevant.
Time frame: 6 months
Readiness Ruler or Substance Use Motivation Ruler score
Asks the respondent to rank his/her motivation to end his/her substance use on a Visual Analog Scale from 1 (Absolutely no motivation to quit) to 10 (No doubt about the decision to be sober) and to list some motivations. The participant will be instructed to provide at least one motivation or more if relevant.
Time frame: 12 months
Hospital Anxiety and Depression scale (HAD) score
assesses the perceived level of depressive (7 items) and anxiety (7 items). For each subscale, a score of 7 or more is considered indexing depression and anxiety caseness.
Time frame: Day 0
Hospital Anxiety and Depression scale (HAD) score
assesses the perceived level of depressive (7 items) and anxiety (7 items). For each subscale, a score of 7 or more is considered indexing depression and anxiety caseness.
Time frame: 3 Months
Hospital Anxiety and Depression scale (HAD) score
assesses the perceived level of depressive (7 items) and anxiety (7 items). For each subscale, a score of 7 or more is considered indexing depression and anxiety caseness.
Time frame: 6 Months
Hospital Anxiety and Depression scale (HAD) score
assesses the perceived level of depressive (7 items) and anxiety (7 items). For each subscale, a score of 7 or more is considered indexing depression and anxiety caseness.
Time frame: 12 Months
Multidimensional Assessment of Thymic States scale (MAThYS) Score
visual analog scale of 20 items relating to individual states as perceived by the patient for the preceding week. Items can be grouped into five quantitative dimensions ranging each from inhibition to excitation: 1. emotional reactivity, 2. thought processes, 3. psychomotor function, 4. Motivation, and 5. sensory perception
Time frame: Day 0
Multidimensional Assessment of Thymic States scale (MAThYS) Score
visual analog scale of 20 items relating to individual states as perceived by the patient for the preceding week. Items can be grouped into five quantitative dimensions ranging each from inhibition to excitation: 1. emotional reactivity, 2. thought processes, 3. psychomotor function, 4. Motivation, and 5. sensory perception
Time frame: 3 Months
Multidimensional Assessment of Thymic States scale (MAThYS) Score
visual analog scale of 20 items relating to individual states as perceived by the patient for the preceding week. Items can be grouped into five quantitative dimensions ranging each from inhibition to excitation: 1. emotional reactivity, 2. thought processes, 3. psychomotor function, 4. Motivation, and 5. sensory perception
Time frame: 6 Months
Multidimensional Assessment of Thymic States scale (MAThYS) Score
visual analog scale of 20 items relating to individual states as perceived by the patient for the preceding week. Items can be grouped into five quantitative dimensions ranging each from inhibition to excitation: 1. emotional reactivity, 2. thought processes, 3. psychomotor function, 4. Motivation, and 5. sensory perception
Time frame: 12 Months
Checklist for Cognitive and Emotional Consequences following stroke (CLCE-24) score
standardized instrument that includes 13 cognitive items, 9 emotional items, and 2 additional open-ended, non-specified items concerning potential additional difficulties not evaluated by the other items. The scoring of each item ranges from 0 (not present) to 3 (present and affecting daily life).
Time frame: Day 0
Checklist for Cognitive and Emotional Consequences following stroke (CLCE-24) score
standardized instrument that includes 13 cognitive items, 9 emotional items, and 2 additional open-ended, non-specified items concerning potential additional difficulties not evaluated by the other items. The scoring of each item ranges from 0 (not present) to 3 (present and affecting daily life).
Time frame: 3 Months
Checklist for Cognitive and Emotional Consequences following stroke (CLCE-24) score
standardized instrument that includes 13 cognitive items, 9 emotional items, and 2 additional open-ended, non-specified items concerning potential additional difficulties not evaluated by the other items. The scoring of each item ranges from 0 (not present) to 3 (present and affecting daily life).
Time frame: 6 Months
Checklist for Cognitive and Emotional Consequences following stroke (CLCE-24) score
standardized instrument that includes 13 cognitive items, 9 emotional items, and 2 additional open-ended, non-specified items concerning potential additional difficulties not evaluated by the other items. The scoring of each item ranges from 0 (not present) to 3 (present and affecting daily life).
Time frame: 12 Months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 24 months is close to that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →